Dansplaining CLOUDS             For release in early 2022

I'm already a quarter-to-third of the way into this novel, but am distracted by SOLASTALGIA (see above). That said, I will get back to CLOUDS in a few months. CLOUDS is only a working title, but the way the story is unfolding, it may be the final title of my next technothriller. I can at least give you some insight as to what I'm working on.

GenoBotics is a new start-up company developed by a couple of Western Australia researchers attempting to use the laws of physics integrated with biomolecular research to develop robotic devices that are as small as molecules. These nanobots can be used medically to deliver drugs to precisely the right place within an individual’s body to help remedy disease. The best example of this technique is in the early stages of development today and will be used to allow oncologists to better treat cancer patients.

Caution: NOT a real nanobot!

Many modern pharmaceuticals intended to fight cancer are designed to interfere inside the targeted malignant cells and cause harm to their DNA. Naturally, the trick is to confine their therapeutic behaviour of the chemo drugs specifically to only the diseased cells making up the tumour. Enter nanorobotics and the guided attack on only unhealthy cells. Enough of the science for now. 

GenoBotics shows much promise, but as often is the case with Australian research, the lack of seed money drives GenoBotics into a merger with Gunn Capital, a large California-based company keen on backing this cutting-edge research.

​

That's where CLOUDS is in January 2021 - to be continued after I put SOLASTALGIA out to the publishers.…

Nanobots at work in a bloodstream... Again, don't take the image too seriously, but it gives at least some idea of what GenoBotics is all about - manipulating VERY small bits within the human body..